Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial

Boccardo, Francesco; Rubagotti, Alessandra; Amoroso, Domenico; Mesiti, M.; Romeo, D; Sismondi, P; Giai, M; Genta, Franco Tarro; Pacini, P; Distante, V.; Bolognesi, Angelo; Aldrighetti, D.; Farris, A.

doi:10.1200/jco.2000.18.14.2718

Cited by 166 publications

(59 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of ovarian ablation/ suppression plus tamoxifen versus chemotherapy alone in premenopausal women generally demonstrate no difference in rates of recurrence or survival between the treatments. 195,206,207 A large Intergroup study in premenopausal women with hormone receptor-positive, node-positive breast cancer studied adjuvant CAF chemotherapy versus CAF plus ovarian suppression with goserelin (CAF-Z) versus CAF-Z plus tamoxifen (CAF-ZT). 198 The results showed no improvement in time to recurrence or overall survival between CAF with CAF-Z.…”

Section: Adjuvant Endocrine Therapymentioning

confidence: 99%

Breast Cancer Version 3.2014

Gradishar¹,

Anderson²,

Blair³

et al. 2014

J Natl Compr Canc Netw

175

117

View full text Add to dashboard Cite

Section: Adjuvant Endocrine Therapymentioning

confidence: 99%

Breast Cancer Version 3.2014

Gradishar¹,

Anderson²,

Blair³

et al. 2014

J Natl Compr Canc Netw

175

117

View full text Add to dashboard Cite

“…daily) in premenopausal women for 5 years (Boccardo et al 2000). A total of 120 patients were randomized to CMF and 124 patients were randomized to goserelin plus tamoxifen.…”

Section: Grocta 02 Trialmentioning

confidence: 99%

A review of adjuvant hormonal therapy in breast cancer

Jones

Buzdar

2004

Endocr Relat Cancer

View full text Add to dashboard Cite

Breast cancer is the most common carcinoma diagnosed in women today excluding non-melanoma skin cancers. It has been well documented that estrogen plays a critical role in its development and is a major target for treatment. For many years, tamoxifen has been the gold standard for adjuvant hormonal therapy in breast cancer patients. With newer products targeting different mechanisms to suppress estrogen production, patients now have many decisions regarding their care. Agents such as luteinizing hormone releasing hormone (LHRH) agonists can suppress ovarian function in premenopausal patients and have been shown to be as effective and even better than chemotherapy (CMF -cyclophosphamide, methotrexate, fluorouracil-containing regimens) in certain patient populations. Tamoxifen continues to be an option as well as toremifene, a similar selective estrogen receptor modulator. With the advent of newer third generation aromatase inhibitors (anastrozole, letrozole and exemestane) toxicities have been documented to be less and in some cases they are more efficacious than the standard, tamoxifen. This article reviews the current data regarding ovarian suppression, ovarian suppression plus tamoxifen, tamoxifen, toremifene, anastrozole, letrozole, and exemestane in the treatment of adjuvant hormonalsensitive breast cancer.

show abstract

“…The INT 0142 trial enrolled 350 women with N -, <3 cm HR + breast cancer to receive either tamoxifen for 5 years or tamoxifen with any form of OA/OS. Unfortunately the trial was closed prematurely because of poor accrual and lacks statistical [63][64][65]. Although all were relatively small trials, none detected a significant difference between the treatment strategies in terms of either DFS or overall survival.…”

Section: Oa/os Combined With Tamoxifen In the Adjuvant Settingmentioning

confidence: 99%

What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?

Prowell

Davidson

2004

The Oncologist

View full text Add to dashboard Cite

Ovarian ablation has been used for more than a century in the treatment of breast cancer. Methods of irreversible ovarian ablation include surgical oophorectomy and ovarian irradiation. Potentially reversible castration can be accomplished medically using luteinizing hormone releasing hormone (LHRH) analogues. In addition, cytotoxic chemotherapy unpredictably produces amenorrhea and primary ovarian failure in 10%-95% of premenopausal women as a function of patient age, cumulative dose, and the specific agents used. In the metastatic setting, ovarian ablation and tamoxifen monotherapies produce comparable outcomes and may be more effective when used together. While many early adjuvant trials of ovarian ablation were methodologically flawed, a more recent meta-analysis by the Early Breast Cancer Trialists' Collaborative Group of 12 properly designed randomized trials found significantly greater disease-free and overall survival rates for women under the age of 50, regardless of nodal status, receiving ovarian ablation as a single adjuvant therapy. Several important issues regarding the role of ovarian ablation in the treatment of breast cancer remain unresolved. Data suggest that ovarian ablation followed by some years of tamoxifen produces similarThe Oncologist 2004;9:507-517 www.TheOncologist.comCorrespondence: Nancy E. Davidson, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, Maryland 21231-1000 Fax: 410-614-4073; e-mail: davidna@jhmi.edu Received November 10, 2003; accepted for publication April 22, 2004. ©AlphaMed Press 1083-7159/2004 The Oncologist ® Breast Cancer LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Discuss the pros and cons of various methods of ovarian ablation, including oophorectomy, radiation therapy, and luteinizing hormone releasing hormone (LHRH) analogues.2. Recall the frequency of chemotherapy-related amenorrhea with commonly used regimens in adjuvant breast cancer treatment.3. Discuss the evidence supporting the use of ovarian ablation in premenopausal women with early-stage breast cancer.4. Discuss the evidence supporting the use of ovarian ablation in premenopausal women with locally advanced and metastatic breast cancer.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME by guest on May 11, 2018http://theoncologist.alphamedpress.org/ Downloaded fromThis material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Prowell, Davidson 508 results to those seen with adjuvant chemotherapy in women with hormone-receptor positive breast cancer; however, the value of combining these modalities is still unclear. Other areas of ongoing investigation include the appropriate duration of therapy with LHRH analogues in the adjuvant setting, the long-term sequelae of ovarian suppression among young breast cancer survivors, and refinement of the populatio...

show abstract

Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial

Abstract: The combination of tamoxifen with ovarian suppression seems to be safe and to yield comparable results relative to standard CMF.

Cited by 166 publications

References 26 publications

Breast Cancer Version 3.2014

Breast Cancer Version 3.2014

A review of adjuvant hormonal therapy in breast cancer

What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?

Contact Info

Product

Resources

About